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The safety and efficacy of foscarnet for prevention of cytomegalovirus (CMV) infection was
evaluated in 19 CMV-seropositive bone marrow transplant (BMT) recipients. All patients re-
ceived intermittent intravenous (iv) foscarnet: 40 mg/kg every 8 h from 7 days before to day 30
after BMT, then 60 mg/kg once a day until day 75. The main toxicity was transient renal
dysfunction, with a >50 pmol/L increase in serum creatinine above baseline in 5 of the 7 auto-
graft recipients and in 6 of the 12 allograft recipients. Only 4 allograft recipients developed CMV
infection during foscarnet prophylaxis, and no patient showed evidence ofCMV disease. Because
3 allograft recipients receiving concomitant iv amphotericin B showed rapid impairment of renal
function, foscarnet prophylaxis should not be given to allograft recipients requiring amphoteri-
cin B; otherwise, foscarnet prophylaxis at this dose appears safe after BMT.
Infection due to cytomegalovirus (CMV) causes signifi-
cant morbidity and mortality among bone marrow trans-
plant (BMT) recipients [1]. In two published series, the prob-
ability ofCMV infection within the first 100 days after BMT
among patients who were CMV-seropositive before trans-
plant was up to 80%and 60%for allograft and autograft recip-
ients, respectively [2, 3]. Mortality was primarily related to
CMV pneumonia, which developed in 37%of allograft and
in 22% of autograft recipients who had evidence of active
CMV infection [2, 3]. Thus, the prevention of CMV infec-
tion and disease after BMT is of foremost importance.
Antiviral chemotherapy aimed at preventing reactivation
of latent virus may be the most promising approach to CMV
prophylaxis both among CMV-seropositive autograft and al-
lograft recipients and among seronegative allograft recipients
who have a seropositive marrow donor. CMV drug prophy-
laxis should cover the early period after BMT in which a
deficiency in CMV-specific immunity can contribute to the
risk of severe CMV disease [4].
The antiviral agent acyclovir given intravenously at high
doses was shown to be partially effective in preventing CMV
infection and disease among seropositive BMT recipients [5].
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Ganciclovir, which is more active than acyclovir against
CMV [6], was evaluated in two recent prospective random-
ized controlled trials among BMT recipients [7, 8]. In these
two studies of early treatment with ganciclovir in patients
who had engrafted (increased neutrophil count after BMT)
and who developed CMV excretion, the incidence of subse-
quent CMV disease was significantly reduced, but severe
neutropenia occurred in 30%-35% of treated patients [7, 8].
The antiviral drug foscarnet (trisodium phosphonofor-
mate) inhibits herpesvirus DNA polymerase activity [9, 10]
and was shown to suppress replication of both laboratory
strains and clinical isolates ofCMV in vitro [11-13]. Clinical
studies among transplant recipients and patients with AIDS
who received foscarnet treatment for severe CMV disease
have shown therapeutic effects and indicate that renal dys-
function is the main adverse experience associated with fos-
carnet, whereas neutrophil counts do not appear to be sub-
stantially affected [14]. Foscarnet could prove as efficient as
ganciclovir in preventing CMV disease in BMT recipients
but could be less toxic to the bone marrow and could there-
fore be used as CMV prophylaxis starting before BMT. In
view of emerging resistance of CMV to ganciclovir [15-18],
foscarnet also could be used as an alternative prophylactic
regimen if resistance to ganciclovir is documented.
We report a prospective phase I-II trial of intermittent
intravenous foscarnet for the prevention of CMV infection
and disease among CMV-seropositive autologous and alloge-
neic BMT recipients. Except for one pilot trial in which 10
CMV-seropositive marrow recipients were given continuous
intravenous administration offoscarnet for prophylaxis [19],
no data on prophylactic regimens using foscarnet among
BMT recipients have yet been published.
Patients and Methods
Patients admitted overa I O-month period to Fred Hutchinson
Cancer Research Center or Swedish Hospital MedicalCenter in
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Seattle were selected for study if they underwent autologous or
allogeneic BMT for hematologic malignancy and if they were
CMV-seropositive before transplant. Exclusion criteria were age
< 12 years, a known allergy to foscarnet, ongoing treatment with
acyclovir or ganciclovir, graft-versus-host disease (GVHD) pro-
phylactic regimen other than cyclosporine plus methotrexate
among allograft recipients [20], proven CMV disease before
transplant, or renal insufficiency (serum creatinine> 133 ,umol/
L) at the time ofinitiation offoscarnet prophylaxis. Patients who
underwent a second marrow transplant or who received a T
cell-depleted marrow graft were also excluded.
The methods of pretransplant conditioning and posttrans-
plant care have been described [21, 22]. Allogeneic transplant
recipients were given cyclosporine plus a short course ofmetho-
trexate as GVHD prophylaxis [20]. No patient received intrave-
nous immune globulins for prevention of infections or GVHD.
Since every patient was CMV-seropositive, blood products
transfused during the study period were not screened for CMV.
Protocoldesign. Because the main adverse effect offoscarnet
is renal dysfunction [14], foscarnet was first evaluated in auto-
graft recipients. Autograft recipients do not receive cyclospor-
ine, which has known nephrotoxic potential [23]. Once foscar-
net proved safe in autograft recipients, the drug was
administered to allogeneic marrow recipients.
Foscarnet sodium solution (Astra Clinical Associates, Hop-
kinton, MA) was supplied in 500-mL glass bottles at 24 mg/rnl,
in an isotonic solution with HCl to adjust pH to 7.4. Each dose
was administered through a central venous line by using an infu-
sion pump. Two regimens of foscarnet were evaluated. The in-
patient regimen was a l-h infusion of foscarnet at 40 mg/kg
every 8 h beginning 7 days before BMT and continuing to day
30 after BMT or until discharge from hospital if earlier. The
calculated total daily dose of 120 mg/kg corresponds to two-
thirds of the dosage (180 rug/kg/day) used as induction treat-
ment for CMV retinitis in patients with AIDS [24, 25]. The
outpatient regimen was a l-h intravenous infusion of foscarnet
daily at a dose of 60 mg/kg given until day 75 after BMT.
Because foscarnet is eliminated by renal excretion [14], the
dosage was adjusted when the calculated creatinine clearance
was < 1.4 ml.zmin/kg. Continuous adjustments were made until
clearance dropped to <0.4 rnl.jrnin/kg, at which time treatment
was stopped. Patients who developed CMV disease were eligible
for available therapy protocols, and participation in the foscar-
net trial was terminated. If treatment of herpes. simplex virus or
varicella-zoster virus infection required acyclovir therapy, fos-
carnet treatment was interrupted and resumed on discontinua-
tion of acyclovir therapy.
PhaseI-safety. To assess potential drug toxicity, the follow-
ing data were recorded daily for inpatients and at least three
times a week for outpatients: white blood cell (WBC) counts
with differential counts, hemoglobin level, platelet counts, and
serum creatinine level. Serum calcium, magnesium, and phos-
phorus concentrations were obtained and liver function tests
were done three times a week. Any clinical symptoms or signs
possibly related to foscarnet treatment were recorded daily. The
rapidity of engraftment during foscarnet treatment was evalu-
ated by determining the number of days required for patients to
reach WEe counts of 1.0 X 109/L, absolute neutrophil counts of
0.5 X 109jL,orplateletcountsof20X 109/Land50X 109/Lon
2 consecutive days not sustained by platelet transfusion~.
Phase II-efficacy. Viral cultures were prepared from
throat, urine, and blood specimens from each patient before
treatment and weekly during and after treatment for a minimum
of 100 days after transplant. Viral cultures from other sites or
from tissue specimens were prepared when clinically indicated.
The clinical specimens were inoculated onto monolayers of hu-
man foreskin fibroblasts and observed for up to 5 weeks. Positive
cultures were identified by the appearance of typical cytopathic
effects, and, in the case of equivocal results, further identifica-
tion was done by indirect immunofluorescence with murine
monoclonal antibodies (Syva, Palo Alto, CA). Serum samples
obtained weekly were tested for IgG antibody to CMV by
ELISA (CMV Stat; Whittaker M.A. Bioproducts, Walkers-
ville, MD).
CMV infection was defined as excretion of the virus or pres-
ence of CMV in tissue specimens but without clinical symp-
toms. CMV disease was defined as presence of CMV in tissue
specimens or in bronchoalveolar lavage (BAL) fluid with asso-
ciated clinical symptoms and signs.
Pharmacokinetics of foscarnet. Blood specimens were ob-
tained from each patient for pharmacokinetic studies at steady
state after 1 week offoscarnet treatment and at weekly intervals
thereafter. Blood (2 mL) was drawn immediately before and at
the end of a given foscarnet infusion and again before the next
consecutive infusion of the drug. Foscarnet plasma levels were
determined by high-performance liquid chromatography with
electrochemical detection as described [26]. The lowest concen-
tration offoscarnet detectable by this assay is 33 umol/L. Calcu-
lation of plasma half-lives (t I / 2) of foscarnet was done as de-
scribed [27].
Results
The clinical characteristics of the 19 patients enrolled in
the study are summarized in table 1. Duration of foscarnet
prophylaxis, median daily dose, and reasons for premature
discontinuation are in table 2.
Safety of Foscarnet
Renalfunction. The main toxicity associated with foscar-
net prophylaxis was impaired renal function (table 3). Of the
7 autograft recipients, 6 (86%) developed renal toxicity, with
an increase in serum creatinine above baseline of>50 ,umol/
L in 5 patients (71 %). In 2 of these 5 patients, impairment
was severe enough to require termination of foscarnet (after
18 and 8 days of foscarnet treatment) and hemodialysis.
Of the 2 requiring hemodialysis, I patient had acute toxic-
ity consisting of diffuse skin rash, hypotension, and renal
failure (peak serum creatinine, 733 ,umol/L). This patient
had been receiving concomitant treatment with granulocyte-
macrophage colony-stimulating factor and intravenous am-
photericin B, which could have contributed to toxicity. Both
foscarnet and amphotericin B were discontinued (on day 10
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Table 1. Characteristics ofmarrow transplant recipients receiving
foscarnet.
Table 3. Toxicity during foscarnet treatment in marrow trans-
plant recipients for prevention of cytomegalovirus infection.:
6 (86) 11 (92)
5 (71) 6 (50)
2 (29) 3 (25)
2 (29) 2 (17)
6 (86) 10 (83)
5 (71) 12 (100)
I (14) 3 (25)
0 I (8)
2 (29) 5 (42)
5 (71) 3 (25)
I (14) 0
I (14) 0
No. of patients
Median age, years (range)
Sex, male/female
Underlying disease
Acute non lymphoblastic leukemia
Acute lymphoblastic leukemia
Chronic myeloid leukemia
Non-Hodgkin's lymphoma
Hodgkin's disease
Conditioning regimen
Cy + FTBI
Bu +Cy
VPI6 + BCNU + Cy
Type of allogeneic transplant
Related donor
HLA-matched
HLA-misma tched
Unrelated donor
HLA matched
Autograft
recipients
7
25 (14-60)
6/1
4
o
o
3
o
5*
I
I
Allograft
recipients
12
31.5 (12-59)
9/3
I
3
7
o
I
7
3
2
9
I
2
Adverse experience
Renal insufficiency
Serum creatinine increase above
baseline
Creatinine increase>50 JLmol/L
Requiring premature discontinuation
of drug
Requiring hemodialysis
Electrolyte abnormalities
Hypocalcemia
Hypophosphatemia
Hypomagnesemia
Hypermagnesemia
Liver failure
Other disorders
Skin rash
Paresthesia
Nausea/vomiting
Autograft
recipients
(n = 7)
Allograft
recipients
(n = 12)
NOTE. Data are no. (%).
Table 2. Duration and dosage of foscarnet treatment in marrow
transplant recipients for prevention of cytomegalovirus infection.
NOTE. Cy, cyclophosphamide; FTBI, fractionated total body irradia-
tion; Bu. busulfan; VPI6, etoposide; BCNU, carmustine.
* Includes I patient who also received busulfan for conditioning.
* 2 related to renal toxicity; I died of idiopathic interstitial pneumonia
after 32 days of treatment: I died ofcardiac toxicity related to chemotherapy
after 26 days of treatment; I had leukemic relapse after 44 days oftreatment.
t 3 related to renal toxicity; 3 required intravenous amphotericin B ther-
apy; I required acyclovir for oral herpes simplex virus infection.
after BMT), and renal function was eventually restored. The
second patient showed an immediate reaction on the day of
the marrow infusion that was attributed to dimethyl sulfox-
ide used for cryopreservation of bone marrow. Although
serum creatinine was 71 J.LmoljL when foscarnet was stopped
(on the day of BMT), creatinine levels rose to a peak of 804
J.Lmol/L in this patient, with recovery to 141 umol/L by day
37 after BMT. Whether renal failure in this patient was re-
lated to foscarnet treatment could not be determined.
The remaining 4 autograft recipients who showed renal
toxicity had transient increases in serum creatinine that did
not necessitate discontinuation of foscarnet. All 4 received
concomitant intravenous amphotericin B treatment for a me-
dian of 10.5 days (range, 2-22). The one autograft recipient
who showed no reduction of renal function also received
concomitant intravenous amphotericin B treatment for 28
days.
Of the 12 allograft recipients, II (92%) developed in-
creases in serum creatinine above baseline that were > 50
J.LmoljL in 6 (50%). Three allograft recipients showed rapid
impairment of renal function requiring premature discontin-
uation of foscarnet after 16, 17, and 19 days of treatment.
Two of the 3 required hemodialysis. One of the dialysed pa-
tients did not improve and died on day 40 after BMT (32
days after foscarnet was stopped) from gram-negative sepsis,
GVHD, and multiorgan failure. Renal function in the other
2 patients normalized within 10 and 14 days after discontin-
uation of foscarnet. These 2 patients had received intrave-
nous amphotericin B during the 3 days before foscarnet treat-
ment was stopped. An additional allograft recipient who was
given foscarnet and concomitant amphotericin B developed
a rapid increase in serum creatinine (peak, 283 J.LmoljL),
which did not necessitate premature withdrawal from the
study but which required temporary discontinuation of fos-
carnet for 8 days. On the basis of the experience in these 3
patients, concomitant use of foscarnet and intravenous am-
photericin B in allograft recipients also receiving cyclospor-
ine was subsequently precluded.
Electrolytes. Hypocalcemia and hypophosphatemia were
frequent after initiation of foscarnet treatment (table 3). No
patient showed clinical symptoms or signs attributable to
Allograft
recipients
(n= 12)
34.5 (10-83)
116 (56-120)
56 (32-60)
5 (71)*
Autograft
recipients
(n = 7)
32 (8-83)
112 (73-120)
60 (32-60)
Time on foscarnet in days,
median (range)
Daily dose in rug/kg, median (range)
Inpatient regimen
Outpatient regimen
No. of patients with premature
discontinuation of
foscarnet treatment (%)
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Table 4. Hematologic monitoring before and during foscarnet
treatment in marrow transplant recipients for prevention of cyto-
megalovirus infection.
Autograft recipients Allograft recipients
Hemoglobin level
Before treatment. g/dL 12.3 (11.0-16.9) 11.2 (8.7-14.3)
Minimum level during
treatment. g/dL 9.5 (9.1-10.2) 9.2 (6.8-10.9)
Time to minimum, days 13(2-35) 15(5-75)
No. of RBC transfusions
per patient 16 (4-18) 14 (7-30)
WBC
Before treatment. X 109/L 7.6 (2.6-14.7) 9.1 (1.0-23.2)
Time to counts ~ 1.0 after
transplant. days* 13(12-27) 18(11-23)
Neutrophil counts
Before treatment, X 109/L 5.6 (2.1-10.1) 4.9 (0.6-13.5)
Time to counts ~0.5 after
transplant. days* 17 (14-27) 17(11-23)
Platelet counts
Before transplant, X 109/L 199 (87-372) 194 (17-2400)
Time to counts ~20 after
transplant. days"! 56 (56->75) 22 (15->75)
Time to counts ~50 after
transplant, days"! 64 (64->75) 24(15--'>75)
evidence of CMV infection while on foscarnet prophylaxis.
One autograft recipient had a BAL for pulmonary infiltrates
after 16 days of foscarnet treatment that was negative for
CMV. Two (29%) of the 7 autograft recipients had CMV
recovered from urine specimens 31 and 67 days after foscar-
net was stopped. No other viruses were isolated in autolo-
gous BMT recipients.
CMV infection occurred in 4 (33%) of the 12 allograft
recipients during foscarnet treatment. Two were receiving
the inpatient regimen and 2 the outpatient regimen. In 4
additional patients (33%), CMV infection developed a me-
dian of 36 days (range, 24-52) after the drug was discontin-
ued. CMV disease did not develop in any allograft recipient
during foscarnet prophylaxis. However, 2 allograft recipients
(17%) developed BAL-proven CMV pneumonia 37 and 42
days after foscarnet was stopped, and both died.
Herpes simplex virus infection was documented in 4 allo-
graft recipients (33%) during foscarnet treatment and in 2
(17%) after the end of treatment. One allograft recipient (8%)
had adenovirus recovered from the throat and from urine 48
days after discontinuation of foscarnet.
Table 5. Virologic results during and after foscarnet treatment in
marrow transplant recipients for prevention of cytomegalovirus
(CMV) infection.
NOTE. RBC, red blood cells; WBC, white blood cells. Data are median
(range).
* Patients who died before reaching specific cell count while on foscarnet
treatment were excluded.
t Counts maintained on at least 2 consecutive days without platelet trans-
fusion support. During foscarnet
treatment
After foscarnet
treatment
changes in serum calcium, magnesium, or phosphorus levels,
but all were supplemented by intravenous infusions when
serum levels were low.
Liver function. Seven patients had liver failure, defined
as total serum bilirubin >85 umol/L, aspartate aminotrans-
ferase >200 units/L, or both (table 3). All cases appeared to
be unrelated to foscarnet use. The decision to terminate fos-
carnet during the study was never based on liver toxicity.
Hematologic effects. The results of hematologic monitor-
ing before and during foscarnet treatment are shown in table
4. Hemoglobin levels dropped during treatment for all auto-
graft recipients and for 10 (83%) of 12 allograft recipients,
reaching a minimum at a median of 13 and I5 days, respec-
tively, after initiation of foscarnet, which corresponded to
the end of the first week after BMT. The median number of
red blood cell transfusions per patient was similar when the 7
patients who completed a full course of foscarnet prophy-
laxis were compared with the entire study population (16 vs.
14 units). No patient had foscarnet discontinued because of
hematologic toxicity.
Efficacy of Foscarnet
The virologic results obtained during and after foscarnet
treatment are shown in table 5. Autograft recipients had no
No. of No. of
patients patients Days after
Virus. culture culture- Day of culture- end of
site positive treatment positive treatment
Autograft recipients
CMV
Throat 0 0
Urine 0 2 31, 67
Blood 0 0
BAL 0/1 16
Allograft recipients
CMV
Throat I II 5* 1.5,35,39.59
Urine 0 5* I. 10. 24, 52, 56
Blood 3 22.67,77 2 36, 82
BAL 2/2 37, 42
Herpes simplex virus
Throat 4 17,25.44.46 2 2. 69
Adenovirus
Throat 0 48
Urine 0 48
NOTE. BAL, bronchoalveolar lavage. If patient had multiple cultures
from same site positive for specific virus. only first culture result is reported.
Ifpatient had positive cultures from different sites. results from each site are
reported once.
* Two patients with CMV viremia during foscarnet treatment began to
excrete CMV from throat and urine after completion of foscarnet prophy-
laxis.
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Table 6. Peak and trough foscamet plasma levels at steady state during intermittent intravenous
(iv) treatment in marrow transplant recipients for prevention of cytomegalovirus infection.
Autograft recipients Allograft recipientsCreatinine
clearance
(mLjminjkg)
Inpatient regimen*
~1.4
0.4-1.3
Outpatient regiment
~1.4
0.4-1.3
Peak
256 (86-405)
288 (156-547)
306 (177-332)
377 (283-382)
Trough
<33 (<33-40)
48 «33-153)
<33:1:
<33 «33-243)
Peak
264 (134-780)
315 (186-588)
387 (52-895)
279 «33-313)
Trough
44 «33-228)
170 «33-568)
<33 «33-108)
<33:1:
NOTE. Data are median (range) values in #LmoljL.
* 40 rng/kg every 8 h infused iv over 1 h.
t 60 rug/kg/day infused iv over I h.
:I: All values <33 ~moljL (detection limit of assay).
Pharmacokinetics of Foscarnet
Table 6 shows the steady-state peak and trough plasma
levels of foscarnet during the inpatient and outpatient regi-
mens at full doses and at reduced doses when the creatinine
clearance was 0.4-1.3 mL/min/kg. Complete data were avail-
able for calculations ofplasma t'/2 offoscarnet in 3 autograft
and 9 allograft recipients. During the inpatient regimen, me-
dian plasma t'/2 of foscarnet was 2.9 h (range, 2.1-8.4)
among autograft recipients and 6.2 h (range, 1.6-15.9)
among allograft recipients. Because most trough plasma lev-
els were below the limit ofdetectability during the outpatient
foscarnet regimen (table 6), plasma t'/2 could be determined
in only 1 allograft recipient and was 6 h. There was no corre-
lation between the magnitude ofplasma t'/2 offoscarnet and
the occurrence ofCMV infection.
Discussion
The most serious toxicity associated with foscarnet pro-
phylaxis in our patients was impaired renal function. An in-
crease in serum creatinine of > 50 ~mol/L above baseline
levels was observed in II (58%) of the 19 patients during
foscarnet treatment. Renal insufficiency led to premature
withdrawal from the study of 5 patients (26%). The relation-
ship of renal insufficiency to foscarnet use was considered
possible in 4 of these 5 patients and was judged unevaluat-
able in the other. The frequency and severity ofrenal toxicity
in our study was in the range ofthat in other studies ofalloge-
neic BMT recipients and AIDS patients [24, 25, 28-32].
Among our allograft recipients, who all received cyclo-
sporine, it rapidly became clear that foscarnet and amphoter-
icin B could not be used simultaneously without develop-
ment of renal insufficiency. Subsequently, foscarnet was
discontinued whenever intravenous amphotericin B was
needed in a patient receiving cyclosporine. However, foscar-
net could be used safely with amphotericin B among auto-
graft recipients who do not receive cyclosporine.
A recent study suggests that renal toxicity associated with
the use offoscarnet can be prevented by hydration with intra-
venous isotonic saline given daily during treatment [32]. In
that study, only 1 (4%) of27 patients with AIDS and CMV
retinitis who received foscarnet with hydration developed
acute renal failure. Peak serum creatinine levels in this group
of patients were significantly lower than in a historical con-
trol group that had received the same foscarnet regimen
without hydration [32]. Reduction of renal toxicity would
allow a larger proportion of BMT recipients to receive a full
course of foscarnet prophylaxis, which may reduce the inci-
dence of CMV infection after transplant.
Abnormalities ofserum electrolytes were common but not
associated with clinical symptoms or signs, suggesting they
were minor adverse effects offoscarnet prophylaxis. Clinical
manifestations may have been prevented by intravenous re-
placement of these compounds when required. In a study of
10 AIDS patients, abnormalities ofserum calcium and phos-
phorus levels were observed in 9 cases but were not accompa-
nied by symptoms and normalized after foscarnet induction
treatment was completed [24]. After BMT, the causes ofhy-
pocalcemia, hypophosphatemia, or hypomagnesemia are
probably multifactorial. Thus, the contribution of foscarnet
to these conditions in our study remains unclear.
A decrease in hemoglobin levels was frequently observed
in this study and was most common early after BMT. How-
ever, the requirements of red blood cell transfusions among
patients who received a full course of foscarnet prophylaxis
did not exceed those reported in earlier studies from our
transplant center among both allograft and autograft recipi-
ents who did not receive foscarnet [33, 34]. The rapidity of
engraftment after BMT was also similar to that among autolo-
gous and allogeneic BMT recipients who were not treated
with foscarnet [3, 35]. Premature discontinuation of foscar-
net prophylaxis was not based on hematologic toxicity in any
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patient. In contrast, studies ofganciclovir in BMT recipients
have reported severe neutropenia that required dose modifi-
cations or discontinuation of the drug in 30%-35% of pa-
tients [7, 8].
CMV infection was prevented in all ofour autograft recipi-
ents but occurred in 33% of allograft recipients during treat-
ment. No patient in this study showed evidence of CMV
disease while receiving foscarnet prophylaxis. These results
compare favorably with those from an earlier pilot study in
which 50% of CMV-seropositive allogeneic BMT recipients
receiving continuous infusions of prophylactic foscarnet de-
veloped CMV infection [19]. Peak plasma levels obtained
with intermittent infusion ofthe drug in our study were more
than double the levels measured with continuous infusion of
foscarnet in that previous trial, which may explain the im-
proved efficacy.
With one exception [17], earlier studies of foscarnet
among BMT recipients used continuous intravenous infu-
sions to administer the drug [13, 19, 28, 29, 36-38]. In one
of these studies that reported data on pharmacokinetics [29],
the steady-state serum levels of foscarnet in 13 allogeneic
BMT recipients who received a daily dose of foscarnet simi-
lar to the dose in our inpatient regimen were 273 ± 43 ~mol/
L (mean ± SE). In our study, the median peak plasma con-
centrations of foscarnet obtained during the inpatient and
outpatient regimens among autograft and allograft recipients
ranged from 256 to 387 ~mol/L. The trough plasma levels of
foscarnet, however, were usually <33 ~mol/L, the detection
limit of the assay [26]. Most clinical isolates of CMV are
inhibited at concentrations of foscarnet of 200-400 ~mol/L
in in vitro cell cultures [14, 18]. Our results indicate that
continuously elevated plasma concentrations offoscarnet do
not appear to be necessary to prevent CMV infection in
BMT recipients.
Prevention of CMV infection and disease appeared effec-
tive only while patients were actively taking the drug. After
discontinuation of foscarnet, CMV infection occurred in 2
autograft (29%) and 4 allograft recipients (33%), and CMV
pneumonia developed in 2 allogeneic BMT recipients (17%).
However, except for I allograft recipient who had CMV ex-
cretion in the throat and urine after a full course offoscarnet
prophylaxis, all of these patients were prematurely with-
drawn from the study and did not receive alternative anti-
viral prophylaxis (data not shown). It remains conjectural
whether a full course of foscarnet treatment or the replace-
ment offoscarnet by drugs such as acyclovir [5] or ganciclo-
vir [7, 8] might have altered the course.
Our data suggest that intermittent intravenous foscarnet
prophylaxis is effective in preventing CMV disease among
patients who tolerate the full course of treatment. However,
foscarnet should not be given to allogeneic BMT recipients
receiving cyclosporine who require intravenous amphoteri-
cin B. With that exception, prophylaxis at the doses used
appears to be safe after both autologous and allogeneicBlvl'T.
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